Search MDGL
MADRIGAL PHARMACEUTICALS, INC.
Nasdaq · CIK 1157601
Last close499.4
Daily change-0.31 (-0.06%)
10 Years gain+3798.52%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MDGL · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
62.6Momentum
100.0Acceleration
100.0Confidence
84.0Annual Revenue8
Quarterly Revenue23
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency7.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 211.95 percentage points.
ROIC expansionROIC improved by 1190.6179 percentage points.
Key Metrics
Revenue Growth TTM449.21%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin100%OK
Operating Margin-26.39%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-251.37%OK
Incremental Operating Margin 3Y-1.42%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.77%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $958.40M | $958.40M | -$300.10M | -$189.55M | -$190.02M | 100% | -31.31% | -19.83% | n/a | n/a |
| 2025 FY Dec 31, 2024 | $180.13M | $180.13M | -$497.88M | -$455.57M | -$457.03M | 100% | -276.39% | -253.72% | n/a | n/a |
| 2025 FY Dec 31, 2023 | $0.00 | $0.00 | -$380.50M | -$324.23M | -$325.71M | n/a | n/a | n/a | n/a | n/a |
| 2024 FY Dec 31, 2022 | $0.00 | $0.00 | -$293.57M | -$224.86M | -$225.07M | n/a | n/a | n/a | n/a | 17.14M |
| 2023 FY Dec 31, 2021 | $0.00 | $0.00 | -$242.48M | -$183.92M | -$184.13M | n/a | n/a | n/a | n/a | 16.54M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.18B | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-050845, 0001628280-25-048559 |
| Revenue Growth TTM | 449.21% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-050845, 0001628280-25-048559 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-009514 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-009514 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-009514 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-050845, 0001628280-25-048559 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001628280-26-050845, 0001628280-25-048559 |
| Operating Margin | -26.39% | Operating Income / Revenue | OK | 0001628280-26-050845, 0001628280-25-048559 |
| ROIC | -251.37% | NOPAT / Average Invested Capital | OK | 0001628280-26-050845, 0001628280-25-048559 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-050845 |
| Current Ratio | 3.2x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 2.46x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-050845 |
| Revenue per Diluted Share | $40.34 | Revenue / Diluted Shares | OK | 0001628280-26-050845, 0001628280-25-048559 |